Trial Profile
A Phase 2a, Randomized, Double-blind, Placebo- and Naproxen Controlled, Parallel-group Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2020
Price :
$35
*
At a glance
- Drugs ASP 7962 (Primary) ; Naproxen
- Indications Musculoskeletal pain
- Focus Proof of concept; Therapeutic Use
- Acronyms OAK
- Sponsors Astellas Pharma Europe Ltd
- 11 Oct 2017 Status changed from active, no longer recruiting to completed.
- 27 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.